---
title: Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction
  and Obesity
date: '2023-08-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37622681/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20230825181052&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: In patients with heart failure with preserved ejection
  fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions
  in symptoms and physical limitations, greater improvements in exercise function,
  and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, ...